来源于大鼠的脱细胞脾基质的制备
2024年2月9日
1.5K 次观看
脱细胞脾基质（DSM）在肝组织工程领域具有广阔的应用前景。该方案概述了制备大鼠DSM的程序，其中包括收获大鼠脾脏，通过灌注使它们脱细胞，并评估所得的DSM以确认其特性。
我们采用了一种新颖的策略，该策略涉及采用脱细胞的脾脏基质作为生物人工肝的替代支架。我们展示了收获大鼠脾脏和制备脱细胞脾基质的详细过程，该基质保留了细胞外基质的宏观结构和成分。我们的方案提供了一个现成的脾脏基质，作为稀缺供体肝脏的替代品。
我们的方案提出了一种制备脱细胞脾脏基质的方法。该方法具有效率、稳定性和微创性，可保持脾脏固有的结构、组成和自然血管网络。它为细胞植入和三维动态培养提供了支架，从而为推进组织工程肝脏的研究奠定了基础。
概述
本协议详细说明了从大鼠脾脏制备去细胞化脾脏基质（DSM）的过程，这对肝脏组织工程学具有重要意义。该方法保留了脾脏的结构和血管网络，为细胞植入和动态培养提供了一个有前景的支架。
关键研究组成部分
科学领域
- 组织工程
- 再生医学
- 生物材料
背景
- 去细胞化基质对于在组织工程中创建支架至关重要。
- 脾脏的结构和成分对于开发肝脏组织很有价值。
- 保持脾脏的自然结构对其功能至关重要。
- 当前的方法旨在在确保稳定性和效率的同时最大程度地减少侵入性。
研究目的
- 为肝脏组织工程提供一种可靠的DSM制备方法。
- 展示细胞外基质成分的保留。
- 为未来在组织工程肝脏应用中的研究奠定基础。
使用的方法
- 从麻醉的动物身上收获大鼠脾脏。
- 通过灌流技术进行去细胞化。
- 评估所得DSM的结构完整性。
- 实施三维动态培养系统。
主要结果
- 去细胞化方法有效地保持了脾脏的宏观结构。
- 所得DSM支持完全的细胞植入。
- 该协议展示了最小的侵入性和高效率。
- 脾脏的天然血管网络在DSM中得以保留。
结论
- DSM是肝脏组织工程的一种有前景的支架。
- 这种方法可以促进再生医学的进步。
- 未来的研究可以在此协议的基础上进行各种应用。
常见问题
什么是去细胞化脾脏基质？
去细胞化脾脏基质是一种通过去除脾脏中的细胞成分而保留其细胞外基质创建的支架。
为什么使用脾脏进行组织工程？
脾脏具有复杂的结构和血管网络，可以支持细胞生长和组织再生。
去细胞化过程如何进行？
该过程涉及灌流技术，以去除细胞同时保持基质的完整性。
DSM的应用有哪些？
DSM可以用作肝脏组织工程和其他再生医学应用的支架。
该方法是否具有侵入性？
该方法设计为最小侵入性，确保所用动物模型的福利。
使用DSM的好处是什么？
DSM提供结构支持，保留自然结构，并增强细胞植入的成功率。
Executive Industry Relevance
Decellularized spleen matrix (DSM) fabrication provides a scalable, structurally preserved scaffold for liver tissue engineering, addressing the shortage of donor organs in end-stage liver disease. By maintaining the spleen's extracellular matrix and vascular architecture, DSM enables robust cell implantation and dynamic culture, supporting predictive confidence in preclinical model development. This capability strengthens the translational pipeline for bioartificial liver (BAL) research and cell therapy innovation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of scaffold biocompatibility and ECM-driven cell behavior for tissue engineering targets.
- Supports biological de-risking by preserving native vascular and matrix structures for functional validation.
- Facilitates predictive confidence in scaffold suitability for downstream liver tissue engineering applications.
Screening & Assay Development
- Provides a reproducible, decellularized matrix for standardized cell seeding and viability assays.
- Ensures assay readiness by maintaining ECM integrity and three-dimensional architecture.
- Enables quantitative assessment of cell engraftment and scaffold performance in dynamic culture systems.
Translational & Preclinical Research
- Aligns with disease-relevant system development for liver failure models and BAL evaluation.
- Supports continuity from scaffold fabrication to preclinical validation of engineered tissue constructs.
- Reduces mechanistic ambiguity by offering a physiologically relevant matrix for translational studies.
Pipeline & Workflow Integration
DSM fabrication integrates into the tissue engineering continuum from scaffold preparation through preclinical model development and translational research for liver therapies.
- Discovery Biology: Advances hypothesis testing on ECM-driven cell function and scaffold-host interactions.
- Screening: Delivers reproducible, quantitative outputs for cell viability and matrix compatibility assays.
- Analytics: Provides histological and structural readouts to compare decellularization efficiency and ECM preservation.
- Translational Research: Bridges scaffold engineering with preclinical evaluation of BAL and cell therapy constructs.
- Enterprise Reuse: Establishes a reusable protocol for scalable scaffold production across tissue engineering programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces biological risk in engineered tissue development.
- Operational Value: Standardizes scaffold preparation for reproducibility and scalability in R&D workflows.
- Strategic Value: Enables informed go/no-go decisions for advancing tissue engineering assets.
- Portfolio Impact: Supports risk-adjusted prioritization of regenerative medicine and BAL pipeline candidates.
Implementation Considerations
- Requires expertise in surgical tissue harvesting and decellularization protocols.
- Needs access to perfusion instrumentation and histological analysis infrastructure.
- Demands cross-team standardization for reproducible scaffold quality and ECM preservation.
- Adaptation may be necessary for different organ sizes or species models.
- Limitations include the need for careful vascular preservation and validation of decellularization completeness.
Biopharma FAQs
Why does null hypothesis testing matter for ECM preservation analysis?
Null hypothesis testing in ECM preservation analysis ensures that observed scaffold integrity is statistically significant and not due to random variation, supporting robust target validation for tissue engineering applications. This approach underpins confidence in the reproducibility and reliability of the decellularization protocol. It enables teams to make data-driven decisions on scaffold suitability for downstream R&D.
How does independent variable isolation in perfusion steps fit the discovery pipeline?
Isolating independent variables such as perfusion reagent concentration and flow rate allows systematic evaluation of their effects on decellularization efficiency and ECM retention. This controlled approach supports optimization and standardization within the early discovery and scaffold development pipeline. It facilitates reproducible outcomes critical for scaling tissue engineering workflows.
What do quantitative dependent variable measurements enable in DSM fabrication?
Quantitative measurements, such as histological scoring and ECM component analysis, enable objective assessment of decellularization completeness and scaffold quality. These outputs provide actionable data for comparing protocol variants and validating scaffold readiness for cell seeding. They support evidence-based advancement decisions in tissue engineering R&D.
Why are replication requirements important for cross-functional scaffold development?
Replication ensures that DSM fabrication yields consistent scaffold quality across batches and operators, which is essential for cross-functional collaboration between discovery, analytical, and translational teams. Reliable replication underpins standardization and scalability, reducing risk in enterprise-level tissue engineering programs. It also supports regulatory and quality expectations for translational research.
What statistical analysis capabilities are required before DSM protocol implementation?
Robust statistical analysis is needed to evaluate decellularization efficiency, ECM preservation, and scaffold reproducibility across experimental runs. Capabilities should include variance analysis, significance testing, and quantitative comparison of histological and structural metrics. These analyses ensure that the protocol meets quality thresholds for integration into biopharma R&D pipelines.
